Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Alectinib (Primary) ; Crizotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2016 Planned End Date changed from 1 Nov 2019 to 1 Dec 2019.
- 03 Oct 2016 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2019.